1 Cash-Producing Stock on Our Watchlist and 2 We Ignore

A company that generates cash is not automatically a winner. Some businesses stockpile cash but fail to reinvest it wisely, limiting their ability to expand.

Cash flow is valuable, but it’s not everything – StockStory helps you identify companies that are truly making it happen. However, there is one cash-generating company that has been successful at converting cash into shareholder value, and two companies that could face some problems.

Last 12 Months Free Cash Flow Margin: 11.1%

Carnival (NYSE:CCL) is one of the world’s largest entertainment travel companies and a leading player in the cruise industry, with exceptional amenities such as planetariums on its ships.

Why Do We Avoid CCL?

1. Stagnant trends in passenger shipping days suggest customers are not adopting its solutions as quickly as the company hopes

2. Weak free cash flow margins of 9.5% over the last two years limit the company’s freedom to invest in growth initiatives, buy back shares or pay dividends

3. Low return on capital reflects management’s struggle to allocate funds effectively

At $25.78 per share, Carnival trades at 12.2 times forward P/E. If you’re considering CCL for your portfolio, check out our FREE research report to learn more..

Last 12 Months Free Cash Flow Margin: 14.7%

Republic (NYSE:RSG), which processes several million tons of recyclable materials annually, provides waste management services for residences, businesses and municipalities.

Why Are We Hesitating About RSG?

1. Scale is a double-edged sword because it limits the company’s growth potential relative to its smaller rivals, as reflected by below-average annual revenue growth of 5.3% over the last two years.

2. Flat unit sales over the past two years suggest demand is weak and the company may need to revise its strategy

3. Estimated sales growth of 3.2% for the next 12 months indicates demand will slow from its two-year trend

Republic Services’ share price of $223.19 indicates a forward P/E valuation ratio of 30.5x. To understand exactly why you should be careful with RSG, check out our full research report (it’s free).

Last 12 Months Free Cash Flow Margin: 26.9%

Founded in 1992 as a scientifically focused alternative to traditional contract research organizations, Medpace (NASDAQ:MEDP) provides outsourced clinical trial management and research services to help pharmaceutical, biotechnology and medical device companies develop new treatments.

Why Are We Watching MEDP?

1. Its core business is healthy and does not need acquisitions to increase sales, as organic revenue growth has averaged 15.9% over the last two years.

2. Share buybacks increased shareholder returns; Annual earnings per share grew 31.7% and exceeded revenue gains over the past five years.

3. Free cash flow margin has increased by 6.4 percent over the past five years, giving the company more chips

Medpace is trading at $483.75 per share, or 28 times forward P/E. Is now the right time to buy? Find out in our full research report, it’s free.

ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market finally realizes it. These aren’t just high-quality businesses. Something is happening to them right now. Elite fundamentals are gaining momentum in the short term; both boxes were checked simultaneously.

Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks – FREE. Get Our Strong Momentum Stocks for Free HERE.

Stocks on our list in 2020 now include familiar names like Nvidia (+1,326% from June 2020 to June 2025) and once-under-the-radar businesses like small-cap company Exlservice (+354% on five-year return). Find your next big winner today with StockStory.